Company registration number 01537424 (England and Wales)
QUADRACHEM LABORATORIES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
Affinia
Swift House
Ground Floor
18 Hoffmanns Way
Chelmsford
Essex
UK
CM1 1GU
QUADRACHEM LABORATORIES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 10
QUADRACHEM LABORATORIES LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
5
77,024
13,576
Tangible assets
6
101,366
101,800
178,390
115,376
Current assets
Stocks
501,319
521,726
Debtors
7
1,244,899
1,639,965
Cash at bank and in hand
705,592
556,813
2,451,810
2,718,504
Creditors: amounts falling due within one year
8
(692,395)
(1,015,698)
Net current assets
1,759,415
1,702,806
Total assets less current liabilities
1,937,805
1,818,182
Creditors: amounts falling due after more than one year
9
-
(32,624)
Provisions for liabilities
(60)
-
0
Net assets
1,937,745
1,785,558
Capital and reserves
Called up share capital
11
129
129
Share premium account
6,295
6,295
Profit and loss reserves
1,931,321
1,779,134
Total equity
1,937,745
1,785,558
QUADRACHEM LABORATORIES LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024
31 December 2024
- 2 -

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 1 September 2025 and are signed on its behalf by:
F Watts
Director
Company registration number 01537424 (England and Wales)
QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

Quadrachem Laboratories Limited is a private company limited by shares incorporated in England and Wales. The registered office is Riverside, Forest Row Business Park, Forest Row, East Sussex, United Kingdom, RH18 5DW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
5 years straight line

Intangible assets are not amortised until they are brought into use.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
4 year straight line
Plant and equipment
4 year straight line
Fixtures and fittings
4 year straight line
Computers
4 year straight line
Motor vehicles
4 year straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.7
Stocks

Stocks are valued at the lower of cost and net realisable value. Cost of finished goods includes overheads appropriate to the stage of manufacture. Net realisable value is based upon estimated selling price less further costs expected to be incurred to completion and disposal.

 

Provision is made for obsolete and slow moving items where net realisable value is expected to reduce below cost.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other debtors, amounts owed by group undertakings and cash and bank balances, are initially measured at the transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method.

QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade and other creditors are initially recognised at transaction price.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

 

The tax charge for the accounting period is shown in the statement of profit or loss as part of tax on profit. The tax liability is shown as corporation tax within creditors due within one year.

Deferred tax

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority. Deferred tax assets are shown under debtors on the balance sheet.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.13
Retirement benefits

For defined contribution schemes the amount charged to profit or loss is the contributions payable in the year. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments.

QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
1.14
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

1.15
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

The valuation of stocks is considered a critical area of judgement and estimation uncertainty by the directors. Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell, in accordance with Section 13 of FRS 102.

 

Management regularly reviews stock for evidence of slow-moving, obsolete, or unsaleable items. The assessment involves significant judgement in estimating the future realisable value of stock items, particularly in light of market conditions, demand forecasts, and the condition or age of the goods.

 

A stock provision is maintained to write down items where the estimated net realisable value is lower than cost. The level of this provision requires management to make estimates based on current selling prices, historical experience, and expected future sales patterns. While the directors believe that the provision is appropriate and reflects current conditions, actual outcomes may differ, which could result in further adjustments to stock values in future periods.

QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
16
16
4
Dividends
2024
2023
Total
Total
£
£
Total dividends
Interim paid
480,188
277,608
480,188
277,608

On 30 June 2023, an interim dividend was declared at a rate of £7.59 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £98,000.

 

On 28 September 2023, an interim dividend was declared at a rate of £6.19 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £79,911.

 

On 28 December 2023, an interim dividend was declared at a rate of £7.72 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £99,697.

 

On 28 March 2024, an interim dividend was declared at a rate of £6.09 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £78,664.

 

On 28 June 2024, an interim dividend was declared at a rate of £6.20 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £80,000.

 

On 27 September 2024, an interim dividend was declared at a rate of £5.93 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £76.599.

 

On 30 December 2024, an interim dividend was declared at a rate of £18.98 per Ordinary share. This dividend was not waived by any shareholders, leaving an actual dividend paid of £244,925.

QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
5
Intangible fixed assets
Software
£
Cost
At 1 January 2024
92,931
Additions
63,450
Disposals
(3,081)
At 31 December 2024
153,300
Amortisation and impairment
At 1 January 2024
79,355
Disposals
(3,079)
At 31 December 2024
76,276
Carrying amount
At 31 December 2024
77,024
At 31 December 2023
13,576
6
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024
367,016
Additions
67,825
Disposals
(84,535)
At 31 December 2024
350,306
Depreciation and impairment
At 1 January 2024
265,216
Depreciation charged in the year
64,225
Eliminated in respect of disposals
(80,501)
At 31 December 2024
248,940
Carrying amount
At 31 December 2024
101,366
At 31 December 2023
101,800
QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
7
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
515,894
900,741
Amounts owed by group undertakings
693,740
693,740
Other debtors
35,265
35,209
1,244,899
1,629,690
Deferred tax asset
-
0
10,275
1,244,899
1,639,965
8
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
188,691
558,254
Corporation tax
166,230
164,411
Other taxation and social security
220,431
201,644
Other creditors
117,043
91,389
692,395
1,015,698

Included within other creditors are net obligations under finance leases and hire purchase contracts of £32,842 (2023: £15,285) which are secured by fixed charges on the assets concerned.

9
Creditors: amounts falling due after more than one year
2024
2023
£
£
Other creditors
-
0
32,624

Other creditors relates to net obligations under finance leases and hire purchase contracts which are secured by fixed charges on the assets concerned.

 

The company has a debenture in place in favour of The Royal Bank of Scotland PLC, dated 7 September 2009, which includes a fixed and floating charge over the undertaking and all property of the company.

10
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
71,126
91,591

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

QUADRACHEM LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
10
Retirement benefit schemes
(Continued)
- 10 -

At the balance sheet date, the company had unpaid defined contribution pension obligations of £5,827 (2023: £5,633).

11
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of 1p each
12,907
12,907
129
129

The company has one class of ordinary share which has full voting, dividend, and capital distribution rights.

12
Financial commitments, guarantees and contingent liabilities

There exists a contingent liability in respect of a bond in favour of HM Revenue and Customs totalling £60,000 (2023: £60,000).

13
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
Total commitments
120,000
-
14
Related party transactions

As per FRS102 paragraph 33.1A, the entity has elected not to disclose its related party balances and transactions on the basis that all entities with which such transactions took place are wholly owned group members.

2024-12-312024-01-01falsefalsefalse01 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityF WattsJ DuncanJ InmanF Watts015374242024-01-012024-12-31015374242024-12-31015374242023-12-3101537424core:IntangibleAssetsOtherThanGoodwill2024-12-3101537424core:IntangibleAssetsOtherThanGoodwill2023-12-3101537424core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3101537424core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3101537424core:ShareCapital2024-12-3101537424core:ShareCapital2023-12-3101537424core:SharePremium2024-12-3101537424core:SharePremium2023-12-3101537424core:RetainedEarningsAccumulatedLosses2024-12-3101537424core:RetainedEarningsAccumulatedLosses2023-12-3101537424core:ShareCapitalOrdinaryShareClass12024-12-3101537424core:ShareCapitalOrdinaryShareClass12023-12-3101537424bus:CompanySecretaryDirector12024-01-012024-12-3101537424core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3101537424core:ComputerSoftware2024-01-012024-12-3101537424core:LeaseholdImprovements2024-01-012024-12-3101537424core:PlantMachinery2024-01-012024-12-3101537424core:FurnitureFittings2024-01-012024-12-3101537424core:ComputerEquipment2024-01-012024-12-3101537424core:MotorVehicles2024-01-012024-12-31015374242023-01-012023-12-3101537424core:IntangibleAssetsOtherThanGoodwill2023-12-3101537424core:OtherPropertyPlantEquipment2024-01-012024-12-3101537424core:CurrentFinancialInstruments2024-12-3101537424core:CurrentFinancialInstruments2023-12-3101537424core:WithinOneYear2024-12-3101537424core:WithinOneYear2023-12-3101537424core:Non-currentFinancialInstruments2024-12-3101537424core:Non-currentFinancialInstruments2023-12-3101537424bus:OrdinaryShareClass12024-01-012024-12-3101537424bus:OrdinaryShareClass12024-12-3101537424bus:OrdinaryShareClass12023-12-3101537424bus:PrivateLimitedCompanyLtd2024-01-012024-12-3101537424bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3101537424bus:FRS1022024-01-012024-12-3101537424bus:AuditExemptWithAccountantsReport2024-01-012024-12-3101537424bus:Director12024-01-012024-12-3101537424bus:Director22024-01-012024-12-3101537424bus:Director32024-01-012024-12-3101537424bus:CompanySecretary12024-01-012024-12-3101537424bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP